1. Introduction {#sec1-vetsci-03-00018}
===============

Feline oral squamous cell carcinoma (FOSCC) is one of the most common cancers in cats \[[@B1-vetsci-03-00018]\]. Over 70% of FOSCC invade the adjacent mandible or maxilla, resulting in bone lysis and a short survival time (less than one year) \[[@B2-vetsci-03-00018]\] (pp. 302--312). Pathogenesis of this cancer is not well-understood and few treatment options are available with limited success.

FOSCC and human head and neck cancer (HNSCC) have a high degree of biological similarity including location of tumors and bone-invasive behavior \[[@B3-vetsci-03-00018]\] (pp. 7--16), \[[@B4-vetsci-03-00018]\] (pp. 125--136), \[[@B5-vetsci-03-00018]\] (p. 218). In humans, HNSCC can be classified in two major categories; human papillomavirus (HPV)-induced and non-viral-associated HNSCC \[[@B6-vetsci-03-00018]\] (pp. 9--22). A favorable prognosis as well as good treatment response was commonly reported in patients with the HPV HNSCC, while most patients with non-viral-associated HNSCC have a poor prognosis. Inactivation or mutation of tumor suppressor genes, especially CDKN2A and TP53, were reported in more than 60% of non-viral associated HNSCC patients \[[@B6-vetsci-03-00018]\] (pp. 9--22).

TP53 is a tumor suppressor gene that encodes p53 protein and has an important role in regulating cell cycle and tumor progression. More than 50% of HNSCC patients were reported to have either TP53 mutations or increased p53 protein (usually due to mutations) detected by immunohistochemistry, which were associated with a poor clinical outcome and opposing tumor progression \[[@B6-vetsci-03-00018]\] (pp. 9--22), \[[@B7-vetsci-03-00018]\] (pp. 73--122). High p53 immunostaining was reported in 43% (10/23) of FOSCCs, while 35% (8/23) of FOSCCs did not have high p53 staining \[[@B8-vetsci-03-00018]\] (pp. 209--214).

Low p16 protein immunoreactivity was found in 48%--83% of human HNSCCs \[[@B9-vetsci-03-00018]\] (pp. 58--60), \[[@B10-vetsci-03-00018]\] (pp. 1931--1934), \[[@B11-vetsci-03-00018]\] (pp. 3630--3633), while high p16 immunoreactivity was found in 37%--59% of human HNSCC \[[@B10-vetsci-03-00018]\] (pp. 1931--1934), \[[@B12-vetsci-03-00018]\] (pp. 649--655). Loss of p16 protein immunoreactivity in human HNSCC correlated with CDKN2A inactivation, especially point mutations, promoter hypermethylation, or homozygous deletion \[[@B6-vetsci-03-00018]\] (pp. 9--22), \[[@B11-vetsci-03-00018]\] (pp. 3630--3633). In contrast, increased p16 immunoreactivity correlated with high-risk-human papilloma virus (HPV)-induced HNSCC \[[@B13-vetsci-03-00018]\] (pp. 2166--2173).

Papillomavirus (PV) is a small, double-stranded circular DNA virus. Its genome has non-coding upstream, early, and late regions. The early region consists of 8 genes (E1 to E8). In high-risk human PVs (HPV), including HPV-16, -18 and -31, E6 and E7 are oncogenic and cause degradation of p53 and pRb during the cell cycle \[[@B14-vetsci-03-00018]\] (pp. 2). An association between the presence of feline catus papillomavirus type 2 (FcaPV2) DNA and p16 and pRb immunostaining in preneoplastic and neoplastic cutaneous SCC lesions has been reported in cats \[[@B15-vetsci-03-00018]\] (pp. 538--545). Increased p16 with decreased pRb was suggested to be a marker for FcaPV in feline cutaneous SCC \[[@B15-vetsci-03-00018]\] (pp. 538--545). However, the presence of papillomavirus and the relationship between p16, p53, and pRb and papillomavirus infection in FOSCC are still unclear. Moreover, FOSCC subtypes have not been classified in this species. We hypothesized that FOSCC could be classified in a manner similar to HNSCC using the immunohistochemical (IHC) pattern and intensity of p16, pRb, and p53 staining. High p16 with a low pRb and p53 immunostaining profile was expected in PV-related FOSCC, while low p16 and either a high or low p53 IHC pattern were proposed in non-PV FOSCC. The goals of our study were to investigate the (1) pattern of immunoreactivity to p16, pRb, and p53 in FOSCC; (2) determine the presence of papillomavirus DNA in 3 FOSCC cell lines and formalin-fixed, paraffin-embedded (FFPE) FOSCC samples with high p16 immunostaining intensity; (3) correlate p16 immunoreactivity and mRNA expression in FOSCC cell lines; and (4) sequence a region of feline p16 cDNA.

2. Materials and Methods {#sec2-vetsci-03-00018}
========================

2.1. Sample Collection {#sec2dot1-vetsci-03-00018}
----------------------

Forty-three FFPE FOSCC specimens originating from the gingiva (*n* = 9), tongue (*n* = 11), sublingual region (*n* = 12), and mandible or maxilla (*n* = 11) were obtained. Three FOSCC cell lines (SCCF1, SCCF2 and SCCF3) previously developed by our laboratory \[[@B16-vetsci-03-00018]\] (pp. 676--683), \[[@B17-vetsci-03-00018]\] (pp. 491--499) and xenograft tissues from nude mice with SCCF1, 2, and 3 were also used. Since positive p16 immunostaining and PV DNA has been reported in feline Bowenoid in situ carcinoma (FBISC) \[[@B15-vetsci-03-00018]\] (pp. 538--545), a FBISC was used as a positive control for p16 and PV DNA. One normal cat gingiva was used for the qRT-PCR, and two normal cat gingiva FFPE samples were used to compare to the FOSCC IHC results.

2.2. Immunostaining {#sec2dot2-vetsci-03-00018}
-------------------

Forty-three FOSCC FFPE, 3 FOSCC xenografts, 1 FBISC and 2 cat gingival tissues were cut into 5-µm sections, deparaffinized, rehydrated, and incubated in antigen retrieval solution (Dako, Carpinteria, CA, USA) at 80 °C for 40 min. and cooled to room temperature for 10 min. Hydrogen peroxide (3%) was used to block endogenous peroxidase and serum-free protein block (Dako) was applied. Samples were incubated overnight at 4 °C with either (1) mouse anti-human p16 monoclonal antibody \[[@B18-vetsci-03-00018]\] (pp. 280--283) (BD Bioscience, clone G175--405, catalog number: 550834; 1:30) in phosphate-buffered saline (PBS); (2) mouse anti-human non-phosphorylated retinoblastoma (pRb) antibody \[[@B15-vetsci-03-00018]\] (pp. 538--545) (BD Bioscience, clone G3--245, catalog number: 554136; 1:40) in PBS; or (3) mouse anti-human p53 antibody \[[@B15-vetsci-03-00018]\] (pp. 538--545) (BD Bioscience, clone PAb 240, catalog number: 554166; 1:100) in PBS. The anti-pRb antibody was specific for nuclear pRb. Anti-mouse monoclonal secondary antibody (Vector Laboratories, catalog number: BA-9200) was used at 1:200 in PBS for 30 min. Slides were stained with Vector ABC Elite complex (Dako) for 30 min, diaminobenzidine tetrahydrochloride (Dako) for 5 min, and with Mayer's hematoxylin for 1 min.

The highest intensity pRb and p53 immunostained samples were used as positive controls, while omission of the primary antibody was used as a negative control. Normal tissue surrounding each tumor served as an internal control. IHC staining of p16, pRb, and p53 was classified into one of 3 categories: (1) absent to low; (2) moderate; and (3) high immunoreactivity, according to the average percentage of immunostained cells and the intensity level of the immunostaining in 5 different 400× fields ([Table 1](#vetsci-03-00018-t001){ref-type="table"}).

2.3. p16 mRNA in 3 FOSCC Cell Lines {#sec2dot3-vetsci-03-00018}
-----------------------------------

RNA was purified from SCCF1, SCCF2, and SCCF3 cells and a normal cat gingiva using the Absolutely RNA RT-PCR miniprep kit (Agilent Technologies, Santa Clara, CA, USA). Normal cat gingiva was collected from a cat euthanized for other reasons, snap frozen in liquid nitrogen, and stored at −80 °C.

The quantitative RT-PCR (qRT-PCR) conditions have previously been described \[[@B19-vetsci-03-00018]\] (pp. 1251--1265). A consensus p16 cDNA sequence (not shown) of exons 1α (126 nucleotides) and 2 (307 nucleotides) was obtained by aligning p16 cDNAs from multiple species including human, chimpanzee, rabbit, cow and mouse and comparing to the updated cat genome sequence (Genbank accession NM 000077.4) from the National Center for Biotechnology Information (NCBI) database. Feline p16 exon 3 was not included in the consensus sequence, because the genomic DNA sequence for exon 3 remains questionable because of disagreements in the alignment of exon 3 between species. Therefore, only sequences of exons 1α and 2 were used for primer design. Primers Fp16m2S (5'-GCCTGGGTCGGAGCCCGATT-3') and Fp162AS (5'-TGCAGCACCACCAGCGTGTC-3') were designed using NCBI Primer-Blast software to specifically detect a 166-nucleotide amplicon spanning the intron between exons E1α and E2 of the p16 gene. The amplicon was partially sequenced and included 95 nucleotides. The amplicon and the forward primer (total of 115 nucleotides) were aligned with p16 cDNA sequences from several species, which confirmed that this region of the predicted cDNA sequence and the junction of exons 1α and 2 were correct ([Figure 1](#vetsci-03-00018-f001){ref-type="fig"}). Feline beta-2 microglobulin (forward primer: 5'-CTACTTCTGGCGCTGCTCTG-3' and reverse primer: 5'-CCTGAACCTTTGGAGAATGC-3') was use as a control housekeeping gene in this experiment.

2.4. Papillomavirus L1 Major Capsid DNA Investigation {#sec2dot4-vetsci-03-00018}
-----------------------------------------------------

The presence of papillomavirus L1 (major capsid) DNA was investigated in SCCF1, F2, and F3 cells as well as all FFPE FOSCC samples that had high p16 immunostaining. FBISC was used as a positive control for FcaPV2 DNA. Liver, spleen, kidney, lymph node, and lung tissues from a normal cat were used as negative controls. DNA was isolated using the DNeasy blood and tissue kit (Qiagen, Hilden, Germany) and quantified using a spectrophotometer (NanoVue, 4282 V2.0.0, Fisher Scientific, Pittsburgh, PA, USA). Four published primer pairs including JMPF/R \[[@B20-vetsci-03-00018]\] (pp. 259--263) (specific for L1-FcaPV2), MY09/11 \[[@B21-vetsci-03-00018]\] (pp. 3074--3083) (consensus primers of the L1 region in many PVs), and JMY2F/R \[[@B22-vetsci-03-00018]\] (pp. 360--366) and JMY3F/R \[[@B22-vetsci-03-00018]\] (pp. 360--366) (specific primers for L1-PV DNA originally amplified from a feline cutaneous SCC) were used to amplify papillomavirus L1 capsid DNA.

2.5. PCR Product Purification and Sequencing {#sec2dot5-vetsci-03-00018}
--------------------------------------------

PCR products were separated on 2% agarose gels and purified using a QIA quick gel extraction kit (Qiagen) and sequenced. Sequences were evaluated using the NCBI BLAST and compared to known sequences in the NCBI database.

2.6. Statistical Analysis {#sec2dot6-vetsci-03-00018}
-------------------------

A one-way ANOVA with a Tukey's post hoc analysis for multiple comparisons was used to examine the difference (1) between ages of cats with FOSCCs in each immunohistochemistry category and (2) p16 mRNA expression in SCCF1, F2, and F3 cells and normal cat gingiva. An unpaired t-test with Welch's correction was used to compare p16 mRNA levels between SCCF3 cells and normal gingiva. For each IHC antibody, the percentage of cases within each scoring criterion and their 95% confidence intervals (CI) were calculated. No overlap between the CIs indicates a statistically significant difference between groups at a significance threshold of *p* = 0.05. Therefore, statistical significance was established at *p* \< 0.05 for all comparisons.

3. Results {#sec3-vetsci-03-00018}
==========

3.1. Relative p16 mRNA Quantification in 3 FOSCC Cell Lines {#sec3dot1-vetsci-03-00018}
-----------------------------------------------------------

Relative p16 mRNA expression in the SCCF1 cell line was significantly greater (55-fold) than the expression in normal cat gingiva, SCCF2, and SCCF3 (*p* \< 0.0001) ([Figure 2](#vetsci-03-00018-f002){ref-type="fig"}). P16 mRNA was reduced in the SCCF3 cells compared to normal gingiva (*p* = 0.027).

3.2. Immunohistochemistry (IHC) {#sec3dot2-vetsci-03-00018}
-------------------------------

Three IHC intensity groups were classified according to the percentage of positive cells and staining intensity as defined in [Table 1](#vetsci-03-00018-t001){ref-type="table"}. There was minimal to no staining variation in different regions of tumors for all antigens. Two samples evaluated for p16 expression were excluded from the pRb and p53 IHC due to insufficient tissue. The intensity of immunoreactivity was categorized as absent to low, moderate, or high ([Figure 3](#vetsci-03-00018-f003){ref-type="fig"}A--C, [Figure 4](#vetsci-03-00018-f004){ref-type="fig"}A--C,E--G ; [Table 2](#vetsci-03-00018-t002){ref-type="table"}). The p16 immunostaining was present in both the nucleus and cytoplasm of the tumor cells. It was found that 18/43 (42%) of the FOSCC had low p16 IHC expression. High p16 immunostaining was present in 6/43 (14%) of the FOSCC. This was significantly lower than the number of tumors with moderate p16 immunostaining (19/43, 44%) ([Figure 5](#vetsci-03-00018-f005){ref-type="fig"}). Nuclear immunoreactivity was used to determine the presence of pRb. Fourteen of 41 (34%) FOSCCs had low to absent pRb staining intensity. In contrast, high intensity of pRb was found in 5/41 (12%) of samples. Most FOSCCs had moderate intensity of pRb staining (22/41, 54%; greater incidence, *p* \< 0.05, compared to low or high intensity) ([Figure 5](#vetsci-03-00018-f005){ref-type="fig"}). p53 IHC staining was also limited to the nuclei. High p53 staining intensity was present in 7/41 (17%) of the samples, while increased p53 immunostaining was not observed in 34/41 (83%) FOSCCs ([Figure 5](#vetsci-03-00018-f005){ref-type="fig"}).

The histopathological characteristics of FOSCC in all of the different IHC groups were similar. The epithelium of normal cat gingiva and tongue had moderate staining intensity for p16 and a low to moderate intensity for pRb and p53 immunostaining ([Figure 3](#vetsci-03-00018-f003){ref-type="fig"}D, [Figure 4](#vetsci-03-00018-f004){ref-type="fig"}D,H). SCCF1 had a high intensity of p16 immunostaining in both the nucleus and cytoplasm of the neoplastic cells ([Table 3](#vetsci-03-00018-t003){ref-type="table"}). In contrast, p16 immunostaining was absent in both SCCF2 and SCCF3 cell lines ([Figure 3](#vetsci-03-00018-f003){ref-type="fig"}E--G).

The average age of FOSCC cats with high intensity p16 staining (mean = 10.6 years, SD = 4.0) was significantly lower than cats in the low intensity group (mean = 14.6 years, SD = 4.3), (*p* \< 0.05) ([Figure 6](#vetsci-03-00018-f006){ref-type="fig"}).

3.3. Papillomavirus L1 capsid DNA amplification: {#sec3dot3-vetsci-03-00018}
------------------------------------------------

PV-L1 capsid DNA was not amplified in the SCCF1, F2, or F3 cell lines or FOSCC samples with high p16 immunostaining intensity, but it was amplified in the FBISC positive control using the JMPF/R primers.

3.4. Sequencing {#sec3dot4-vetsci-03-00018}
---------------

A consensus p16 cDNA sequence was obtained by aligning p16 cDNAs from multiple species and comparing them to the updated cat genomic sequence (Genbank accession NM000077.4) from the NCBI database. Using The Blast Sequence Analysis Tool (<http://www.ncbi.nlm.nih.gov/books/NBK21097/>), a predicted feline p16 cDNA sequence was generated ([Figure 7](#vetsci-03-00018-f007){ref-type="fig"}). RT-PCR products amplified in the SCCF1 cell line and normal cat gingiva were sequenced and aligned to the predicted feline p16 cDNA, which confirmed the predicted splice site for exons 1α and 2. The RT-PCR sequences had 100% homology with the predicted p16/CDKN2A cDNA of *Felis catus*. Although the full-length p16 cDNA could not be amplified due to the difficulty in designing functional RT-PCR primers for the cat and inadequate sequence information for the very short open reading frame of exon 3, a partial p16 cDNA sequence (Genbank accession: Banklt1884793 Seq1 KU508421) was amplified, confirmed, and found useful to measure p16 mRNA in feline cells and tissues ([Figure 7](#vetsci-03-00018-f007){ref-type="fig"}).

4. Discussion {#sec4-vetsci-03-00018}
=============

High intensity p16 and low intensity p53 and pRb immunostaining correlated with a subset of high-risk HPV-induced HNSCC in humans \[[@B10-vetsci-03-00018]\] (pp. 1931--1934). In contrast, low intensity p16 immunostaining was reported in non-viral-associated HNSCC, which had either mutation or inactivation of CDKN2A \[[@B11-vetsci-03-00018]\] (pp. 3630--3633), \[[@B23-vetsci-03-00018]\] (pp. 77--81). For this reason, p16 IHC serves as a useful tool for HNSCC classification and prognosis in humans.

The number of FOSCC with high intensity p16 staining found in this study (6/43, 14%) was greater than in a previous study (2/30, 7%) \[[@B18-vetsci-03-00018]\] (pp. 280--283). Based on HNSCC in humans, we hypothesized that the majority of FOSCCs would have either low or high p16. However, the results of the present study show that there were significant differences between cats and humans with oral cancer. Most FOSCC in cats had a moderate staining intensity of p16 and smaller subsets had high or low staining intensity. In humans, high intensity p16 staining was associated with high-risk HPV infection and a better prognosis, while loss of p16 immunostaining was associated with CDKN2A inactivation and a worse clinical outcome \[[@B6-vetsci-03-00018]\] (pp. 9--22), \[[@B7-vetsci-03-00018]\] (pp. 73--122). However, the connection between p16 immunostaining and prognosis in FOSCC has not been reported, therefore, the clinical outcome of FOSCC with different p16 staining intensity should be investigated further.

Interestingly, cats with FOSCC and abundant p16 protein were significantly younger than cats with FOSCC and low levels of p16. In humans, HPV was suspected to be involved in the pathogenesis of HNSCC in young patients \[[@B24-vetsci-03-00018]\] (pp. 249--258), \[[@B25-vetsci-03-00018]\] (pp. 1843--1849). Therefore, we speculate that the pathogenesis of FOSCC in younger cats with high p16 staining intensity may differ from FOSCC in older cats with low p16. It is also possible that FOSCC with high p16 intensity may be associated with a feline papillomavirus infection that has not been discovered yet. We were unable to amplify papillomavirus L1 capsid DNA from the SCCF1 cell line and FOSCC FFPE samples that had high intensity of p16 staining. The combined data from two studies showed that papillomavirus capsid DNA was only amplified in 3 of 47 FOSCC samples (p16 expression was not measured in these two studies) \[[@B26-vetsci-03-00018]\] (pp. 359--361), \[[@B27-vetsci-03-00018]\] (pp. 68--74). In another study, only two of thirty FOSCC samples had high p16 immunoreactivity, but FcaPV was not detected in these two specimens \[[@B18-vetsci-03-00018]\] (pp. 280--283). Therefore, papillomavirus infection may only be involved rarely in the pathogenesis of FOSCC. However, these relatively small sample numbers may be inadequate to draw a definitive conclusion on the role of papillomavirus in FOSCC. All primer pairs used to amplify papillomavirus DNA in these experiments were designed against the L1-regions of FcaPV2 and the conserved sequences from an alignment between different types of PVs. These primers may not detect other PVs that possibly exist in the FOSCC samples.

Low p53 and pRb were found in a subset of high risk-HPV-induced HNSCCs that had high p16 \[[@B10-vetsci-03-00018]\] (pp. 1931--1934). The interaction between the high-risk human papillomavirus E6 protein and p53 causes degradation of p53, while the interaction between E7 protein and pRb results in degradation of pRb and increases free p16 \[[@B14-vetsci-03-00018]\] (p. 2), \[[@B28-vetsci-03-00018]\] (pp. 405--415). A lack of pRb correlated with high p16 and FcaPV2 infection in feline cutaneous squamous cell carcinoma \[[@B15-vetsci-03-00018]\] (pp. 538--545). In this study, high p16 immunoreactivity was associated with low p53 in 5 out of 6 samples; however, only 1 of 6 FOSCC with high p16 had low pRb. Instead, FOSCC samples with high p16 were more likely to have moderate pRb (4 out of 6 samples). Therefore, the association between p16, p53, and pRb in FOSCC is unclear. Other proteins may be involved in up-regulation of p16 in FOSCC or the relationship between pRb and p16 in FOSCC may be different from HNSCC in humans.

We found that forty-two percent of FOSCC had low p16. These figures were greater than a previous study with 2/30 (7%) of cats having low p16 \[[@B18-vetsci-03-00018]\] (pp. 280--283). These differences may be due to regional differences and location of the FOSCC tissues within the oral cavity, as well as larger sample size, which might explain the greater proportion of low p16 that was found in the present study. The most common tumor location in the previous study was gingiva (12/30), while in this present study there was an even proportion between gingiva (9), tongue (11), sublingual (12) and mandible or maxilla (11). In addition, FOSCC in cats from different countries may have a distinct pathogenesis and protein expression. Loss of p16 immunostaining correlated with inactivation of the CDKN2A in HNSCC \[[@B11-vetsci-03-00018]\] (pp. 3630--3633). Hypermethylation of a CpG island in the CDKN2A promoter region and homozygous deletion mutation of p16 has been reported in various cancers, particularly HNSCC \[[@B6-vetsci-03-00018]\] (pp. 9--22), \[[@B11-vetsci-03-00018]\] (pp. 3630--3633), \[[@B29-vetsci-03-00018]\] (pp. 686--692), \[[@B30-vetsci-03-00018]\] (pp. 1197--1206). It is possible that many FOSCCs are associated with mutation or inactivation of the CDKN2A tumor suppressor gene. Unfortunately, there are still gaps in the feline whole genome sequence in the NCBI database and the genomic sequences surrounding the CDKN2A exons remain undefined. Completion of the feline p16 gene sequence will be essential for evaluating inactivation of the CDKN2A in FOSCC.

We found that p16 mRNA levels in SCCF1, SCCF2, and SCCF3 cell lines were consistent with p16 immunostaining in the xenograft samples. In particular, a high level of p16 mRNA expression was present in the SCCF1 cell line, which also showed a high p16 staining intensity.

Low p16 has been observed more often in the late stages of HNSCC (T3 or T4) \[[@B9-vetsci-03-00018]\] (pp. 58--60), which has a less favorable prognosis compared to HPV-induced-HNSCC \[[@B7-vetsci-03-00018]\] (pp. 73--122), \[[@B29-vetsci-03-00018]\] (pp. 686--692). p16 protein expression was suggested to possess prognostic utility in squamous cell carcinoma of the nasal planum in cats, since cats with high p16 had a longer survival compared to those with loss of p16 \[[@B31-vetsci-03-00018]\] (pp. 269--273). In addition, transfection of wild-type p16 into HNSCC cell lines decreased cancer cell proliferation in vitro \[[@B30-vetsci-03-00018]\] (pp. 1197--1206), \[[@B32-vetsci-03-00018]\] (pp. 3250--3253).

Increased p53 is the predictor of TP53 mutation in various cancers including HNSCC \[[@B33-vetsci-03-00018]\] (pp. 2455--2463). Seventeen percent (7/41) of FOSCC samples had a high intensity of p53 immunostaining. Therefore, somatic mutation of TP53 with increased expression and decreased activity of p53 may occur in some FOSCCs. Increased p53 immunostaining was not observed in 83% of FOSCCs. Lack of or low p53 immunostaining can be found in cells with TP53 inactivation as well as normal p53 expression. However, a subset of FOSCCs with low p53 immunostaining might be associated with TP53 inactivation, since 24%--53% of HNSCC in humans with low p53 immunostaining were related to TP53 mutations \[[@B33-vetsci-03-00018]\] (pp. 2455--2463), \[[@B34-vetsci-03-00018]\] (pp. 36). Twenty-seven percent (11/41) of FOSCC samples in this study had low p53 and p16 staining. Since CDKN2A encodes both the p16 and p14 proteins, inactivation of CDKN2A may also lead to loss of p14 if one of the common exons is inactivated or deleted. p14 stabilizes p53 by preventing the association between MDM2 and p53. Without p14, MDM2 independently binds and targets p53 protein for proteosomal degradation \[[@B35-vetsci-03-00018]\] (pp. 862--873). There is still no evidence that CDKN2A inactivation causes both p16 and p14 loss in HNSCC. However, the loss of both p16 and p14 IHC was found in 30% (9/30) of non-small cell lung cancers (NSCLC) and 67% (19/28) of pancreatic cancers \[[@B36-vetsci-03-00018]\] (pp. 1162--1168). Inactivation of CDKN2A is a potential mechanism to indirectly inhibit p53 protein expression. PV-related FOSCC was suspected in 12% (5/41) of samples that had low p53 and high p16 immunostaining intensity. However, papillomavirus capsid DNA was not amplified in these samples. Our data suggests that inactivation of the TP53 or CDKN2A may occur in FOSCC to directly or indirectly silence p53 expression. Inactivation of CDKN2A, as well as TP53, in the pathogenesis of FOSCC will require further investigation.

5. Conclusions {#sec5-vetsci-03-00018}
==============

The immunohistochemical staining patterns for p16, Rb, and p53 have been described for FOSCC and provide important information on the potential pathogenesis and future improvements in the diagnosis, treatment, and prognosis of FOSCC. The immunohistochemistry patterns of p16, p53, and pRb in FOSCC were different from human HNSCC and feline cutaneous SCC. The p16 immunostaining intensity was consistent with relative p16 mRNA levels in three FOSCC cell lines. Partial sequence analysis of p16 DNA was completed and shown to be identical for a FOSCC with high p16 and normal feline gingiva. There is still limited evidence that papillomavirus plays a role in FOSCC, but it should not be excluded as a potential pathogenic mechanism. It is likely that subclassifications of oral SCC in cats based on tumor suppressor gene expression will guide research investigations and prognosis and treatment of cats with OSCC in the future.
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![Alignment between human, chimpanzee, rabbit, cat, cow and mouse p16 cDNA sequences. The 115-nucleotide RT-PCR amplicon spanning the junction between exons 1α and 2 of the cat p16 cDNA was aligned with the corresponding regions of p16 from the indicated species. The dot indicates the first nucleotide of exon 2. An asterisk (\*) indicates a nucleotide that is identical between all the aligned sequences, a colon (:) indicates a nucleotide of strongly similar properties between aligned sequences and a period (.) indicates a nucleotide of weakly similar properties between aligned sequences. Alignment was performed using ClustalW2 software (European Bioinformatics Institute ftp server).](vetsci-03-00018-g001){#vetsci-03-00018-f001}

![Relative p16 mRNA expression in 3 feline oral squamous cell carcinoma (FOSCC) cell lines compared to normal cat gingiva. All qRT-PCR was repeated in triplicate using 3 different passages of each cell line. The relative p16 mRNA expression in SCCF1 (*n* = 3) was significantly greater (55-fold) than in SCCF2 (*n* = 3), SCCF3 (*n* = 3), and normal gingiva (\*\* *p* ≤ 0.0001). p16 mRNA was significantly reduced in the SCCF3 cells compared to normal gingiva (\* *p* = 0.027).](vetsci-03-00018-g002){#vetsci-03-00018-f002}

![FOSCC, oral tissue, cat, immunohistochemistry photomicrographs. Absent to low p16 immunoreactivity. Very low intensity of p16 immunostaining was present in less than 20% of the neoplastic cells (**A**); moderate p16 staining. Moderate levels of p16 immunoreactivity were present in the cytoplasm of some of the FOSCC cells. Small numbers of nuclei had a high intensity of p16 immunostaining (**B**); high intensity p16 staining. Both nuclear and cytoplasmic p16 immunostaining were prominent in the tumor cells (**C**); normal gingival epithelium, cat. Immunoreactivity to p16 protein in normal cat oral tissues. There was a moderate intensity of p16 staining in normal gingival epithelium (**D**); p16 IHC in a mouse xenograft tumor derived from the SCCF1 cell line. High p16 intensity (brown color) was observed in both the nuclei and cytoplasm of SCCF1 tumor cells (**E**); p16 IHC in a mouse xenograft tumor derived from the SCCF2 cell line. Low to absent p16 intensity was present in SCCF2 cells (**F**); p16 IHC in a mouse xenograft tumor derived from the SCCF3 cell line. Low to absent p16 staining intensity was observed (**G**). (DAB/hematoxylin).](vetsci-03-00018-g003){#vetsci-03-00018-f003}

![FOSCC, oral tissue, cat. FOSCC with absent to low intensity of pRb staining. Less than 50% of the neoplastic cells had a low intensity of nuclear immunostaining to pRb (**A**); microscopic features of moderate pRb intensity in FOSCC. Moderate pRb staining intensity was present in more than 50% of neoplastic nuclei (**B**); high intensity of pRb in FOSCC. Almost all of the neoplastic nuclei have high intensity immunostaining for pRb protein (**C**); normal gingival epithelium, cat. pRb IHC of normal cat oral tissue. Moderate pRb staining intensity was present in epithelial cell nuclei (**D**); microscopic features of absent to low intensity of p53 staining in FOSCC. The immunoreactivity to p53 protein was absent from neoplastic nuclei (**E**); microscopic features of moderate p53 staining intensity in FOSCC. Moderately intense immunoreactivity to p53 was present in most of the neoplastic nuclei (**F**); microscopic features of high intensity p53 immunostaining in FOSCC. Prominent p53 immunostaining (dark brown color) was visible within neoplastic nuclei (**G**). Normal gingival epithelium, cat. Immunostaining of p53 protein in normal cat oral tissue. Low intensity p53 staining was present (**H**) (DAB/hematoxylin).](vetsci-03-00018-g004){#vetsci-03-00018-f004}

![Immunohistochemistry of p16, p53, and pRb in spontaneous feline oral squamous cell carcinomas. The numbers in parentheses (percentages) indicate the 95% confidence intervals (CIs) of each group. No overlap between CIs indicates statistically significant differences between groups (*p* ˂ 0.05). Significantly different from absent to low group is indicated by (**a**) Significantly different from moderate group is indicated by (**b**) Significantly different from high group is indicated by (**c**).](vetsci-03-00018-g005){#vetsci-03-00018-f005}

![The average age of cats with FOSCC with high intensity p16 staining group (*n* = 6, mean = 10.6 years, SD = 4.0) was significantly lower than the age of cats in the absent to low p16 immunostaining intensity group (*n* = 18, mean = 14.5 years, SD = 4.3) (\* *p* \< 0.05). There was no significant difference between the average ages of cats with absent to low and moderate p16 (*n* = 18) and between moderate and high p16 staining intensity. The plus sign represents the means, the middle line of the boxes indicates the medians, the boxes contain 50% of samples, and top and bottom error bars represent maximum and minimum age of cats in each group, respectively.](vetsci-03-00018-g006){#vetsci-03-00018-f006}

![Feline p16 predicted cDNA sequence for exons 1α and 2. The feline p16 cDNA sequence shown was obtained from the updated cat genome sequence (Genbank accession NM 000077.4) after alignment with known cDNA sequences from other species. The sequenced feline p16 cDNA amplicon (Genbank accession: Banklt1884793 Seq1 KU508421) (115 nucleotides in bold) consists of the downstream end of exon 1α and the beginning of exon 2. The ATG start site of exon 1α is underlined.](vetsci-03-00018-g007){#vetsci-03-00018-f007}
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###### 

Classification of p16, pRb, and p53 immunohistochemistry staining.

  Protein       Absent to Low                                                               Moderate                                                                                                                                      High
  ------------- --------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------
  p16           \<20% of cancer cells have low cytoplasmic intensity                        20%--50% of cancer cells have low to intermediate cytoplasmic and nuclear staining intensity                                                  \>50% of cancer cells have high cytoplasmic and nuclear staining
  pRb and p53   \<20% of cancer cells have low to intermediate nuclear staining intensity   20%--50% of cancer cells have high nuclear staining intensity, or \>50% of cancer cells have low to intermediate nuclear staining intensity   \>50% of cancer cells have high nuclear staining intensity
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###### 

Signalment and immunohistochemistry data from 43 cats with FOSCC.

  Signalment   IHC Results                                                     
  ------------ ------------- ---- ------ --------------- ---------- ---------- ----------
  1            DSH           FS   14     Gingiva         Low        Moderate   Low
  2            DSL           MC   20     Gingiva         Low        Low        N/A
  3            DSH           F    11     Gingiva         High       High       Low
  4            Himalayan     FS   16     Gingiva         Moderate   Moderate   Low
  5            DSH           MC   15     Gingiva         Moderate   Moderate   Moderate
  6            DSH           FS   N/A    Gingiva         Moderate   Moderate   Low
  7            Himalayan     MC   12     Gingiva         Low        High       Low
  8            DSH           MC   11     Gingiva         Moderate   Moderate   High
  9            DSH           MC   17     Gingiva         Moderate   Moderate   Low
  10           DSH           MC   13     Tongue          Low        High       High
  11           Siamese       FS   13     Tongue          Low        Low        Moderate
  12           DSH           MC   16     Tongue          Low        Moderate   Low
  13           DLH           MC   11     Tongue          Moderate   Low        Low
  14           DSH           FS   13     Tongue          Low        Low        Low
  15           Exotic SH     F    10     Tongue          Moderate   N/A        Low
  16           DSH           MC   11.5   Tongue          Moderate   Moderate   Low
  17           DLH           F    10     Tongue          Moderate   Moderate   Low
  18           DSH           MC   6      Tongue          Low        Low        High
  19           DSH           FS   15.5   Tongue          Low        Low        High
  20           DSH           F    10     Tongue          Moderate   Moderate   Low
  21           DSH           F    12     Sublingual      Low        Low        Moderate
  22           Angora        FS   7      Sublingual      Low        Moderate   Low
  23           DSH           MC   4      Sublingual      Moderate   Low        Low
  24           DSH           M    14+    Sublingual      Moderate   Low        High
  25           Persian       FS   13.5   Sublingual      High       Moderate   Low
  26           DSH           MC   12     Sublingual      Moderate   Moderate   Low
  27           DSH           M    12.5   Sublingual      Low        Low        Low
  28           DLS           FS   17     Sublingual      Low        High       High
  29           DSH           FS   19     Sublingual      Low        Moderate   Low
  30           DSH           FS   14     Sublingual      Moderate   Moderate   Low
  31           DLH           MC   17     Sublingual      Low        Moderate   Low
  32           DSH           FS   19     Sublingual      Low        N/A        Low
  33           DSH           MC   13     Mandi or Maxi   High       Moderate   High
  34           DSH           MC   12     Mandi or Maxi   High       Low        Low
  35           DLH           F    6.5    Mandi or Maxi   Moderate   Moderate   Low
  36           DSH           MC   12     Mandi or Maxi   High       Moderate   Low
  37           DSH           F    16     Mandi or Maxi   Low        Low        Low
  38           DSH           F    20     Mandi or Maxi   Low        Low        Low
  39           DSH           FS   2      Mandi or Maxi   High       Moderate   Low
  40           DLH           MC   14     Mandi or Maxi   Moderate   Low        Low
  41           Himalayan     F    11     Mandi or Maxi   Moderate   Moderate   Low
  42           DSH           MC   13     Mandi or Maxi   Moderate   Moderate   Low
  43           DSH           FS   9      Mandi or Maxi   Moderate   High       N/A

DSH: Domestic short hair, DLH: Domestic long hair, F: Female, FS: Spayed female, M: Male, MC: Castrated male, N/A: Not applicable, Mandi or Maxi: Mandible or Maxilla.
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###### 

Immunoreactivity to p16, p53, and pRb in three FOSCC Xenograft tumors and primary Feline Bowenoid in situ cutaneous Squamous Carcinoma (FBISC).

  Sample   p16 IHC   p53 IHC    pRB IHC
  -------- --------- ---------- ---------
  SCCF1    High      Low        Low
  SCCF2    Low       Low        Low
  SCCF3    Low       Moderate   Low
  FBISC    High      Low        Low
